At the American Academy of Neurology 2024 annual meeting, Dr. Richard Nowak from Yale University discussed recent advancements in the therapeutic management of myasthenia gravis (MG). The LUMINESCE phase 3 trial, involving 188 participants, assessed the efficacy and safety of satralizumab, a humanized interleukin-6 receptor monoclonal antibody. The trial demonstrated a statistically significant, albeit modest, improvement in the Myasthenia Gravis Activities of Daily Living score with satralizumab treatment.

Dr. Nowak also highlighted part A of the ADAPT NXT trial, which compared fixed-cycle dosing to every-other-week dosing of intravenous efgartigimod. The study revealed that efgartigimod was well tolerated across both dosing regimens, allowing for individualized treatment plans. Additionally, the CHAMPION MG open-label extension trial showcased the long-term efficacy and safety of ravulizumab in patients with anti-acetylcholine receptor antibody-positive generalized MG, demonstrating sustained efficacy over 164 weeks. A smaller retrospective study suggested that initiating eculizumab treatment within the first two years of MG diagnosis could provide greater clinical benefits compared to later initiation.

Reference: Nowak R. Myasthenia Gravis Highlights From AAN 2024. MDEdge Neurology. Accessed June 27, 2024.